On Friday, Jubilant Life Science said that it has got an approval from the US health regulator to market its generic zolmitriptan orally disintegrating tablets, an anti migraine drug in the American market.

Jubilant Life Sciences said in a regulatory filing, the company has received nod from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for zolmitriptan orally disintegrating tablets in strengths of 2.5 mg and 5 mg.

The drug of the company is a generic version of AstraZeneca’s Zoming-ZMT tablets that is used for acute treatment of migraine headaches in adults.

Get profitable free intraday tips